SECFilings.com reported the publication of an article showcasing Axim Biotechnologies Inc (OTCMKTS:AXIM) clinical progress and portfolio in light of Zynerba’s Phase II Cannabidiol gel patch failure. The clinical trial of 188 subjects with refractory epilepsy showed that those administered a low dose of ZYN002 recorded an 18.4% median drop in seizures versus a 14% drop for high dosages and an 8.7% decline for placebo. The objective missed and the absence of a dose-dependent response indicate that the underlying delivery mechanism was ineffective. The therapeutic even failed to surpass placebo in any of the secondary objectives.
Zynerba’s clinical study failure underlines numerous key points that cannabis shareholders may want to carefully contemplate when selecting their next investments. Investors should do their groundwork when investing in firms with small clinical pipelines. Zynerba’s other clinical program is ‘ZYN001’, which is a THC prodrug patch in its Phase I clinical studies, which indicates that the failure of ‘ZYN002’ in Phase 2 clinical studies took a considerable toll on the stock price. Shareholders should seek out firms with extensive portfolios where a single failure won’t endanger the entire firm.
Working with Hemps may be more tough than many researchers and companies had initially thought. Hemps have intricate interactions with the body and don’t at all times behave as researchers would anticipate. Investors should look for firms that have extensive expertise in medicine, and positive indications of efficacy in earlier Phase 1 and pre-clinical studies to increase their odds of success.
It may be tempting to consider that Hemps have been over-hyped after Zynerba’s failure, but shareholders shouldn’t give up on that space. Zynerba’s clinical study did reflect that Hemp is well-tolerated and safe, while GW Pharmaceuticals plc’s clinical plans have validated that both Hemp and THC have broad promise in curing underlying problems, it is a matter of effectively providing the molecules in the right dosages.
Axim Biotechnologies resolves many of these key issues with a broad clinical and patent portfolio, robust clinical expertise, and progress recorded to date.